Summary
Medtronic plc's 2019 10-K filing reveals a company focused on global health through its diverse medical technology offerings. The company operates across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. These segments provide a broad range of products and services aimed at alleviating pain, restoring health, and extending life for millions worldwide. Financially, the company demonstrated a modest increase in net sales for fiscal year 2019, driven by strong performance in its Restorative Therapies and Diabetes segments, although this was partially offset by a divestiture within the Minimally Invasive Therapies Group. Medtronic continues to prioritize its three growth strategies: Therapy Innovation, Globalization, and Economic Value, evident in its ongoing investment in research and development and its expansion into emerging markets. The company also maintains a strong commitment to returning capital to shareholders through share repurchases and dividends, supported by robust operating cash flow.
Financial Highlights
55 data points| Revenue | $30.56B |
| Cost of Revenue | $9.15B |
| Gross Profit | $21.40B |
| SG&A Expenses | $10.42B |
| Operating Income | $6.27B |
| Interest Expense | $1.44B |
| Net Income | $4.63B |
| EPS (Basic) | $3.44 |
| EPS (Diluted) | $3.41 |
| Shares Outstanding (Basic) | 1.35B |
| Shares Outstanding (Diluted) | 1.36B |
Key Highlights
- 1Medtronic operates through four primary segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes, offering a wide range of medical technologies.
- 2Net sales saw a modest increase in fiscal year 2019, driven by growth in the Restorative Therapies and Diabetes segments, though impacted by a divestiture in the Minimally Invasive Therapies Group.
- 3The company is actively pursuing its growth strategies: Therapy Innovation, Globalization (with emerging markets growing 6% in FY19), and Economic Value, focusing on value-based healthcare solutions.
- 4Research and Development expenses remained substantial, reflecting a commitment to innovation, with R&D spending at $2.3 billion for fiscal years 2019 and 2018.
- 5Medtronic maintained a strong liquidity position, with $4.4 billion in cash and cash equivalents and $5.5 billion in current investments at the end of fiscal year 2019.
- 6The company actively returned capital to shareholders, with an authorized share repurchase program of $11.0 billion, having utilized approximately $3.8 billion by April 2019.
- 7Medtronic's balance sheet shows significant goodwill ($39.9 billion) and other intangible assets ($20.5 billion), primarily resulting from past acquisitions and reflecting strategic investments in technology and brands.